deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03277261

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) (ULTIMATE 1)

Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)

Sponsor: TG Therapeutics, Inc.

Conditions Relapsing Multiple Sclerosis (RMS)
Interventions IV Placebo Oral Placebo Teriflunomide Ublituximab
Updated 25 times since 2017 Last updated: Nov 5, 2021 Started: Sep 19, 2017 Primary completion: Jul 23, 2020 Completion: Nov 6, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Relapsing Multiple Sclerosis (RMS), this trial is completed. The trial is conducted by TG Therapeutics, Inc. and has accumulated 25 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Oct 2017 – ~Mar 2018 · 5 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Oct 2019 · 8 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Jan 2022 · 7 months · monthly snapshot~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2021 — Jan 2022 [monthly]

    Completed PHASE3

  5. Mar 2021 — Jun 2021 [monthly]

    Completed PHASE3

▶ Show 20 earlier versions

  1. Feb 2021 — Mar 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  10. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  12. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  13. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  14. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  15. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  16. Oct 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  17. Feb 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  18. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

  19. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  20. Oct 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

    First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TG Therapeutics, Inc.
Data source: TG Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amherst, United States , Carlsbad, United States , Dallas, United States , Detroit, United States , Franklin, United States , Kansas City, United States , Knoxville, United States , Long Beach, United States , Miami, United States , Northbrook, United States and 4 more locations